Online citations, reference lists, and bibliographies.

Phase II Study Of Pomalidomide In Combination With Prednisone In Patients With Myelofibrosis And Significant Anemia.

Naval Daver, Aditi Shastri, Tapan Mahendra Kadia, Kate Juliet Newberry, Naveen Pemmaraju, Elias J Jabbour, Linghsa Zhou, Sherry A. Pierce, Jorge E. Cortes, Hagop M Kantarjian, Srdan Verstovsek
Published 2014 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
We evaluated pomalidomide with prednisone for myelofibrosis (MF) with significant anemia (hemoglobin < 10 g/dL). Patients (n = 29; 18 RBC-transfusion dependent) received 0.5mg pomalidomide daily in continuous 28-day cycles with prednisone given for the first 3 cycles only. Six (21%) patients responded (median response duration 11.4 months), including four who achieved RBC-transfusion-independence per the Delphi criteria and two who achieved clinical improvement (in platelets and spleen, respectively) per the International Working Group for Myelofibrosis Research and Treatment criteria. Grade 3 toxicity occurred in 1 patient (fatigue). Pomalidomide with prednisone is safe therapy with modest activity in patients with MF and anemia. ClinicalTrials.gov Identifier: NCT00946270.
This paper references
10.1182/blood-2002-09-2928
A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia.
Ruben Mesa (2003)
10.1182/blood.v122.21.394.394
Phase 3 Study Of Pomalidomide In Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis With RBC-Transfusion-Dependence
Francesco Passamonti (2013)
10.1200/JCO.2009.22.6548
Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.
Alfonso Quintás-Cardama (2009)
10.1038/leu.2010.254
A phase-2 trial of low-dose pomalidomide in myelofibrosis
Kebede H. Begna (2011)
10.1056/NEJMoa1110557
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
Srdan Verstovsek (2012)
10.1111/j.1365-2141.2005.05524.x
Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients.
Francisco Cervantes (2005)
10.1016/j.leukres.2010.07.015
What are RBC-transfusion-dependence and -independence?
Robert Peter Gale (2011)
10.1182/blood-2008-07-170449
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.
Francisco Cervantes (2009)
10.1016/j.leukres.2013.07.007
Modest activity of pomalidomide in patients with myelofibrosis and significant anemia.
Naval Daver (2013)
10.1182/blood-2006-03-009746
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).
Ayalew Tefferi (2006)
10.1182/BLOOD.V122.21.2822.2822
Pomalidomide In MPN–associated Myelofibrosis With Cytopenia: Results Of The Mpnsg 01-09 Study
Frank Stegelmann (2013)
10.1002/ajh.21598
Phase1/-2 study of Pomalidomide in myelofibrosis.
Ruben Mesa (2010)
10.1053/j.seminhematol.2004.02.011
The chronic myeloproliferative disorders: clonality and clinical heterogeneity.
Jerry L Spivak (2004)
10.1002/cncr.22365
The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients.
Ruben Mesa (2007)
10.1200/JCO.2008.21.7356
Pomalidomide is active in the treatment of anemia associated with myelofibrosis.
Ayalew Tefferi (2009)
10.1002/cncr.21827
Thalidomide therapy for myelofibrosis with myeloid metaplasia.
Deborah A. Thomas (2006)
10.1111/j.1600-0609.2009.01266.x
Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level.
Jocelin Huang (2009)
10.1200/JCO.2004.08.160
Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial.
Monia Marchetti (2004)
10.1182/blood-2006-02-004572
Lenalidomide therapy in myelofibrosis with myeloid metaplasia.
Ayalew Tefferi (2006)
10.1002/ajh.22233
Long-term outcome of pomalidomide therapy in myelofibrosis.
Kebede H. Begna (2012)
10.1056/NEJMoa1002028
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.
Srdan Verstovsek (2010)
10.1016/S1053-4296(03)00031-6
CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment.
Andy M Trotti (2003)
10.1200/JCO.2012.42.3863
Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs.
Robyn M. Emanuel (2012)



This paper is referenced by
10.3892/etm.2017.5209
Thalidomide and its analogues: A review of the potential for immunomodulation of fibrosis diseases and opthalmopathy.
Ting T. Liu (2017)
10.1016/j.bjhh.2016.04.003
Primary myelofibrosis: current therapeutic options
Paula de Melo Campos (2016)
10.1002/jcph.455
Population Pharmacokinetics of Pomalidomide
Yan Li (2015)
10.1002/cpdd.470
An Open‐Label, Phase 1 Study to Assess the Effects of Hepatic Impairment on Pomalidomide Pharmacokinetics
Yan Li (2019)
10.1007/s00280-016-3012-z
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
Jeffrey C. Bryan (2016)
10.2147/TCRM.S69211
Profile of pomalidomide and its potential in the treatment of myelofibrosis
Krisstina L. Gowin (2015)
10.1080/17474086.2017.1366853
Immunotherapy based approaches in myelofibrosis
Lucia Masarova (2017)
10.1002/jcph.1145
In Vivo Assessment of the Effect of CYP1A2 Inhibition and Induction on Pomalidomide Pharmacokinetics in Healthy Subjects
Yan Li (2018)
10.2147/CPAA.S171735
A Phase I, open-label, randomized, crossover study in healthy subjects to evaluate the bioavailability of, and the food effect on, a pomalidomide oral liquid suspension
Yan Li (2018)
10.1016/J.HTCT.2019.03.001
Guideline on myeloproliferative neoplasms: Associacão Brasileira de Hematologia, Hemoterapia e Terapia Cellular
Renato Vitor da Silva Tavares (2019)
10.17925/OHR.2016.12.02.71
An Exciting New Era in the Treatment of Myeloproliferative Neoplasms
Naval Daver (2016)
10.1007/s11899-019-00527-7
The Rationale for Immunotherapy in Myeloproliferative Neoplasms
Lucia Masarova (2019)
10.2147/OTT.S102504
Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned
Javier Pinilla-Ibarz (2016)
10.1080/14656566.2016.1252333
Myelofibrosis: an update on drug therapy in 2016
Prithviraj Bose (2016)
10.1016/J.BJHH.2016.04.003
Primary myelofibrosis: current therapeutic options
Paula de Melo Campos (2016)
10.1007/s00277-016-2697-8
Managing patients with myelofibrosis and low platelet counts
Haifa Kathrin Al-Ali (2016)
10.1517/21678707.2016.1171139
Is there a role for pomalidomide in the treatment of myelofibrosis?
Samah Alimam (2016)
10.1007/s40265-017-0797-y
Pharmacotherapy of Myelofibrosis
Douglas Tremblay (2017)
10.1038/s41375-018-0077-1
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet
Tiziano Barbui (2018)
10.1016/bs.pmbts.2016.09.004
Myeloproliferative Neoplasms: Molecular Drivers and Therapeutics.
Gary W. Reuther (2016)
10.1097/MOH.0000000000000320
‘JAK–ing’ up the treatment of primary myelofibrosis: building better combination strategies
Rita Assi (2017)
10.2147/CPAA.S144606
Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function
Yan Li (2017)
10.3324/haematol.2015.126821
Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis
Naval Daver (2015)
10.1007/s11899-018-0447-9
Management of Myelofibrosis-Related Cytopenias
Prithviraj Bose (2018)
10.1038/leu.2016.299
Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis
Richard F Schlenk (2017)
Semantic Scholar Logo Some data provided by SemanticScholar